AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

AnaptysBio, Inc.NASDAQ: ANAB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin widens to 97.6%

Gross margin was 97.6% in Q1 FY2026, up 145.9 pp from a year earlier. On a trailing-twelve-month basis it was 116.4%, up 166.6 pp year over year. Over 3 fiscal years it widened by 862.2 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
97.6%-102.1 pp QoQ
Last fiscal yearDec 2025
99.0%+178.5 pp YoY
LTMMar 2026
116.4%+166.6 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+145.9 pp——
1 year+178.5 pp——
3 years+862.2 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.0%
Year-over-year change
+178.5pp

Gross Margin vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 gross margin of 116.4% is the highest of the 7 companies compared; the peer median is 97.7%.
  • Its year-over-year change of +166.6 pp is the highest of 5, against a peer median of -2.0 pp.
  • Over three fiscal years its change of +862.2 pp compares with a peer median of +6.7 pp.
ANAB Competitors Peer median
Gross Margin for ANAB and competitors
Company Period LTM level YoY 3-year change
ANABAnaptysBio, Inc.LTM Mar 2026116.4% +166.6 pp+862.2 pp
IMVTImmunovant, Inc.LTM Sep 2026100.0% ——
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
QTTBQ32 Bio Inc.LTM Mar 202699.3% —-0.7 pp
DNTHDianthus Therapeutics, Inc.LTM Jun 202696.0% -4.0 pp+0.0 pp
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
XNCRXencor, Inc.LTM Jun 202643.3% -18.0 pp+112.9 pp
MLTXMoonLake ImmunotherapeuticsFY2025— ——
ODTXOdyssey Therapeutics, Inc.—— ——
ANNXAnnexon, Inc.FY2025— ——
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
Peer median (excluding ANAB) 97.7%-2.0 pp+6.7 pp

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue63.18M10.29M17.16M91.28M234.6M
Cost of Revenue98.5M88.8M132.28M163.84M2.42M
Gross Profit(35.32M)(78.51M)(115.13M)(72.56M)232.18M
Gross Margin-55.9%-763.2%-671.0%-79.5%99.0%
Research & Development98.5M88.8M139.62M163.84M135.97M
Selling, General & Admin21.49M36.64M41.95M42.39M50.74M
Operating Expenses21.49M36.64M49.29M42.39M184.28M
Depreciation & Amortization2.09M2.34M652K2.4M2.42M
EBITDA(55.71M)(105.26M)(156.42M)(92.74M)69.25M
EBITDA Margin-88.2%-1023.2%-911.7%-101.6%29.5%
Operating Income(56.81M)(115.15M)(164.41M)(114.95M)47.9M
Operating Margin-89.9%-1119.4%-958.3%-125.9%20.4%
Interest Income431K7.55M18.87M19.79M13.5M
Interest Expense1.45M21.11M18.08M50.09M79.89M
Other Income / Expenses(982K)(13.55M)788K(30.28M)(60.96M)
Income Before Tax(57.8M)(128.7M)(163.62M)(145.23M)(13.07M)
Pre-Tax Margin-91.5%-1251.1%-953.7%-159.1%-5.6%
Income Tax Expense024K(4K)3K164K
Net Income(57.8M)(128.72M)(163.62M)(145.23M)(13.23M)
Net Margin-91.5%-1251.3%-953.7%-159.1%-5.6%
EPS (Basic)(2.11)(4.57)(6.08)(5.12)(0.46)
EPS (Diluted)(2.11)(4.57)(6.08)(5.12)(0.46)
Weighted Avg Shares27.43M28.17M26.92M28.38M27.79M
Weighted Avg Shares (Diluted)27.43M28.17M26.92M28.38M31.34M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.